New hope for rare leukemia: targeted pill shows promise in early trial

NCT ID NCT04409639

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests a drug called cobimetinib in people with a rare blood cancer (CMML) that has certain gene mutations. The goal is to see if the drug can shrink or control the cancer. Fourteen adults with either new or treatment-resistant CMML will take the drug daily in 3-week-on, 1-week-off cycles. The main focus is how many patients respond, and safety is also tracked.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelomonocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington, 98109, United States

  • Huntsman Cancer Institute at University of Utah

    Salt Lake City, Utah, 84112, United States

  • Oregon Health and Science University

    Portland, Oregon, 97239, United States